Newest version of 'the pill' confers same stroke risk as old pill
A new study finds that the updated birth control pills pose a significant stroke risk for women. The risk is similar to that of first-generation pills and higher than non-users.
Thrombosis
Articles tagged with Thrombosis
UK researchers shed new light on a cause of recurrent miscarriages
A prospective study found that women with Factor V Leiden mutations had low live birth rates compared to those without the mutation. The research suggests that targeted anti-blood clotting treatment may be beneficial for these women, and screening is recommended.
SourceEuropean Society of Human Reproduction and Embryology·JournalHuman Reproduction·DateJan 29, 2002
Survey of intensive care units concludes that the current approach to preventing deep vein thrombosis is substandard
A survey of intensive care units found that many strategies to prevent deep vein thrombosis (DVT) were not being used, including support stockings and low molecular weight heparin. Physicians need more education on latest techniques to reduce DVT incidence, and fundamental research is needed to understand the condition.
Study: The rate of clots forming inside stents is three times higher than generally appreciated
A new study has found that the rate of clots forming inside stents is three times higher than generally appreciated, with a 3.5% risk for patients with acute coronary syndromes. This finding may prompt cardiologists to rethink their approach to stent placement and consider alternative treatments to lower this risk.
Fatal thrombotic disease in designer mice lacking vascular thrombomodulin
Research on designer mice lacking vascular thrombomodulin has led to a greater understanding of the protein's importance in preventing blood clots. The study reveals that this critical regulator is necessary for maintaining normal blood coagulation, with severe consequences for those lacking it.
Extended prophylactic treatment after hip or knee replacement reduces risk of venous thrombosis
A study found that extended-duration prophylaxis significantly reduced the incidence of symptomatic VTE in patients undergoing total hip or knee replacement. The reduction in risk is equivalent to about 20 symptomatic events per 1000 patients treated.
Heart boost can improve outcome for sickest heart attack patients
Researchers at Duke University Medical Center found that artificially intensifying the heart's pumping action, known as aortic counterpulsation, showed modest but significant benefits for the sickest heart attack patients. The technique, combined with clot-busting drugs, reduced six-month mortality rates by 4% compared to treatment alone.
Reprogenesis reports preclinical studies in PNAS on tissue engineered product to prevent (re)stenosis
Vascugel, a perivascular tissue engineered implant, prevents intimal hyperplasia by regulating biochemical compounds involved in blood vessel repair. The study supports the potential use of Vascugel to enhance cardiovascular procedures and reduce costs associated with (re)stenosis.
SourceFeinstein Kean Healthcare·JournalProceedings of the National Academy of Sciences·DateJun 5, 2000
First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95
The METHRO II study found that H 376/95 was effective in preventing venous thrombo-embolism in patients undergoing total hip or total knee replacement surgery. The incidence of venous thrombo-embolism was significantly lower with the highest dosage of H 376/95 compared to dalteparin.
Common anti-inflammatory drug rescues low-growth fetuses in mouse study
Researchers develop a mouse model for intrauterine growth retardation and find that administering indomethacin during pregnancy can rescue underweight fetuses. The study provides promising insights into the underlying biochemistry of IUGR and identifies a potential therapeutic approach.
New findings point to new target to block angiogenesis
Scientists at Vanderbilt University Medical Center have identified a new target for drugs that inhibit tumor angiogenesis. Thromboxane A2 receptor antagonists show promise in blocking endothelial cell migration and preventing blood vessel formation associated with tumors.
Certain Heart Attack Patients Are Under-Treated
A study by researchers at UCSF Medical Center found that the electrocardiogram is highly inaccurate for patients with left bundle-branch block (LBBB), leading to under-treatment. This affects approximately 100,000 Americans with LBBB who experience myocardial infarction every year.
Clot-Busters As Effective As Surgery To Clear Blockages In Legs
A new study found that clot-busting drugs can save legs as effectively as invasive surgery, reducing the need for open surgical procedures by over 30%. The experimental drug, recombinant urokinase, showed no significant difference in death or amputation rates between surgical and non-surgical patients.
Molecular Defect Could Be Mysterious Cause Of Blood Disorder
Researchers at Johns Hopkins Medicine have identified a unique molecular defect responsible for polycythemia vera, a blood disorder that can be difficult to diagnose. The finding may lead to the development of a definitive test for the condition, which could potentially increase patient lifespan.
B-Vitamins Lower Homocysteine Levels In The Blood; May Reduce Vessel Damage In Stroke Patients
Researchers found that a vitamin supplement with folic acid, B-6, and B-12 reduced homocysteine levels and improved biochemical markers in the blood of 27 patients who had suffered a stroke. The study suggests that lowering homocysteine may have multiple biological effects on endothelial cells.
Ultrasound May Speed Clot-Busters' Effect In Stroke, Reduce Risk To Patients
Researchers found that low-frequency ultrasound enhances the effectiveness of thrombolytic drugs in dissolving blood clots deep within the brain. This combination therapy may reduce the duration and doses of medication needed, minimizing risks of bleeding and other complications associated with stroke treatment.
New Ultrasound Contrast Agent Leads To Full Patient Recovery
A new ultrasound contrast agent, Levovist, has been used to treat an ischemic stroke in a German patient. The agent revealed the blocked artery and allowed doctors to dissolve the clot with thrombolytic rTPA, restoring blood flow to the brain within 40 minutes of admission.
New Software Simulates How Blood Clots Dissolve
Researchers developed CLOTSIM, a computer model simulating blood clot dissolution, to provide critical information on thrombolytic agents. The program helps predict clinical outcomes and tailor therapies to reduce patient risks.